PTC Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$56.6M
Doctors Paid
1,083
Transactions
9,790
2024 Total
$8.4M
Payment Breakdown by Category
Research$49.2M (87.0%)
Consulting$2.8M (4.9%)
Royalty/License$482,303 (0.9%)
Travel$294,283 (0.5%)
Food & Beverage$98,485 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $49.2M | 5,286 | 87.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.5M | 340 | 6.3% |
| Consulting Fee | $2.8M | 697 | 4.9% |
| Royalty or License | $482,303 | 20 | 0.9% |
| Travel and Lodging | $294,283 | 605 | 0.5% |
| Food and Beverage | $98,485 | 2,433 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $71,845 | 42 | 0.1% |
| Education | $54,467 | 356 | 0.1% |
| Grant | $11,675 | 8 | 0.0% |
| Charitable Contribution | $7,000 | 3 | 0.0% |
Payments by Type
Research
$49.2M
5,286 transactions
General
$7.3M
4,504 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY LEIOMYOSARCOMA | $6.9M | 9 | 556 |
| AN OPEN-LABEL, SAFETY STUDY FOR ATALUREN (PTC124) PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | $2.5M | 0 | 794 |
| AN OPEN-LABEL TRIAL TO ADDRESS THE SAFETY OF THE SMARTFLOW MR-COMPATIBLE VENTRICULAR CANNULA FOR ADMINISTERING ELADOCAGENE EXUPARVOVEC TO PEDIATRIC SUBJECTS | $2.4M | 3 | 98 |
| TQT STUDY - PHASE 1 PLACEBO AND POSITIVE CONTROLLED STUDY TO ASSESS THE EFFECT OF SINGLE THERAPEUTIC (400 MG) AND SUPRATHERAPEUTIC VATIQUINONE (1200 MG) DOSES ON QTCF PROLONGATION BY USING CONCENTRATION-EFFECT MODELLING (CEM) | $2.1M | 0 | 18 |
| EFFICACY AND SAFETY STUDY OF VATIQUINONE FOR THE TREATMENT OF MITOCHONDRIAL DISEASE SUBJECTS WITH REFRACTORY EPILEPSY | $2.0M | 2 | 463 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY AND OPEN-LABEL EXTENSION | $1.8M | 0 | 450 |
| A PHASE IB STUDY OF PTC596 IN CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA AND HIGH GRADE GLIOMA | $1.8M | 0 | 39 |
| AN OPEN-LABEL, SAFETY STUDY FOR PREVIOUSLY TREATED VATIQUINONE (PTC743) SUBJECTS WITH INHERITED MITOCHONDRIAL DISEASE | $1.7M | 0 | 267 |
| AN OPEN-LABEL TRIAL TO ADDRESS THE SAFETY OF THE SMARTFLOW MR COMPATIBLE VENTRICULAR CANNULA FOR ADMINISTERING ELADOCAGENE EXUPARVOVEC TO PEDIATRIC SUBJECTS | $1.6M | 3 | 33 |
| A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA (MOVE-FA) | $1.5M | 2 | 183 |
| A PHASE 1B STUDY OF UNESBULIN (PTC596) IN COMBINATION WITH DACARBAZINE IN PATIENTS WITH LOCALLY RECURRENT, UNRESECTABLE OR METASTATIC RELAPSED/REFRACTORY LEIOMYOSARCOMA | $1.5M | 0 | 92 |
| PHASE 1B STUDY OF PTC299 IN RELAPSED/REFRACTORY ACUTE LEUKEMIAS | $1.2M | 0 | 155 |
| AN OPEN-LABEL, SAFETY STUDY FOR PREVIOUSLY TREATED ATALUREN PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY | $1.2M | 0 | 248 |
| PHASE 1 STUDY TO INVESTIGATE THE ABSORPTION, METABOLISM, AND EXCRETION OF 14C PTC923 FOLLOWING A SINGLE ORAL DOSE ADMINISTRATION IN HEALTHY MALE VOLUNTEERS | $1.2M | 0 | 10 |
| PHASE 2 CLINICAL PHARMACOLOGY STUDY TO ASSESS DYSTROPHIN LEVELS IN SUBJECTS WITH NMDMD BEFORE AND AFTER TREATMENT WITH ATALUREN | $1.1M | 0 | 87 |
| A PHASE 1 STUDY TO INVESTIGATE THE PHARMACOKINETICS OF PTC743 AND THE ABSORPTION, METABOLISM, AND EXCRETION OF 14C-PTC743 IN HEALTHY VOLUNTEERS | $1.0M | 0 | 9 |
| A PHASE 3 STUDY OF PTC923 IN SUBJECTS WITH PHENYLKETONURIA | $970,020 | 0 | 74 |
| A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND SAFETY OF VATIQUINONE FOR THE TREATMENT OF FRIEDREICH ATAXIA | $896,011 | 0 | 44 |
| AN OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, TWO-PERIOD CROSSOVER STUDY COMPARING THE BIOEQUIVALENCE OF DEFLAZACORT DISPERSIBLE TABLET TO EMFLAZA DEFLAZACORT TABLET IN HEALTHY ADULT SUBJECTS | $869,415 | 0 | 8 |
| A PHASE 1B STUDY OF PTC596 IN COMBINATION WITH DACARBAZINE IN PATIENTS WITH LOCALLY RECURRENT, UNRESECTABLE OR METASTATIC RELAPSED-REFRACTORY LEIOMYOSARCOMA | $766,581 | 0 | 72 |
| A PHASE 3 OPEN-LABEL STUDY OF PTC923 (SEPIAPTERIN) IN PHENYLKETONURIA | $738,581 | 0 | 55 |
| NELSON OBSERVATIONAL STUDY | $733,501 | 0 | 7 |
| Phase 1 open label single dos 4-group study to eveluate the PK and Safety of Ataluren in subjects with various severities of impaired Hepatic Function and healthy subjects | $704,260 | 0 | 6 |
| A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE ABSORPTION, METABOLISM, AND EXCRETION OF 14C-PTC518 IN HEALTHY MALE PARTICIPANTS | $641,294 | 0 | 6 |
| Open-Label, Safety Study for Previously Treated Ataluren (PTC124) Patients with Nonsense Mutation Dystrophinopathy in North America | $570,036 | 0 | 84 |
| LONG-TERM OPEN-LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF VATIQUINONE IN PATIENTS WITH FRIEDREICH ATAXIA | $527,481 | 0 | 120 |
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OF PTC857 IN ADULT SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (CARDINALS) | $523,990 | 3 | 99 |
| A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF SEPIAPTERIN | $521,334 | 0 | 35 |
| EVALUATING THE THERAPEUTIC POTENTIAL OF MAPT SPLICING MODULATIONIN HUMAN NEURONAL MODELS OF TAUOPATHY | $475,400 | 0 | 4 |
| A Phase 1 Study to investigate the absorption and metabolism of 14-C deflazacort following single oral dose administration in healthy subjects | $416,003 | 0 | 9 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. Migvis Monduy, M.d, M.D | Neurology with Special Qualifications in Child Neurology | Miami, FL | $23,546 | $0 |
| Oscar Mayer, M.d, M.D | Pediatrics | Philadelphia, PA | $22,683 | $0 |
| Dr. Paldeep Atwal, Md, MD | Clinical Genetics (M.D.) | West Palm Beach, FL | $22,583 | $0 |
| Phillip Pearl, Md, MD | Neurology with Special Qualifications in Child Neurology | Boston, MA | $22,208 | $0 |
| Dr. Roberto Zori, Md, MD | Clinical Genetics (M.D.) | Gainesville, FL | $21,037 | $0 |
| John Osborne, Md, MD | Cardiovascular Disease | Grapevine, TX | $20,713 | $0 |
| Kevin Flanigan, Md, MD | Neurology with Special Qualifications in Child Neurology | Columbus, OH | $20,145 | $0 |
| Vamshi Rao, Md, MD | Neurology with Special Qualifications in Child Neurology | Chicago, IL | $19,430 | $0 |
| Dr. Gerard Vockley, Md, Phd, MD, PHD | Medical Genetics, Ph.D. Medical Genetics | Pittsburgh, PA | $19,202 | $0 |
| Dr. Clifton Gooch, M.d, M.D | Neurology | Tampa, FL | $18,563 | $0 |
| Dr. Richard Bedlack, M.d. Ph.d, M.D. PH.D | Neurology | Durham, NC | $18,140 | $0 |
| William Burnette, Md, MD | Neuromuscular Medicine | Nashville, TN | $18,093 | $0 |
| Andres Gelrud, M.d, M.D | Gastroenterology | Miami, FL | $17,500 | $0 |
| Dr. Horacio Kaufmann, M.d, M.D | Neurology | New York, NY | $17,071 | $0 |
| Farida Abid, Md, MD | Neurology with Special Qualifications in Child Neurology | Houston, TX | $16,836 | $0 |
| Dr. Joseph Ray, M.d, M.D | Clinical Genetics (M.D.) | Galveston, TX | $16,333 | $0 |
| Dr. Robert Enelow, M.d, M.D | Internal Medicine | Washington, DC | $15,572 | $0 |
| Erin Furr Stimming, M.d, M.D | Neurology | Houston, TX | $13,481 | $0 |
| Dr. Paul Watkins, Md, MD | Gastroenterology | Chapel Hill, NC | $13,125 | $0 |
| Dr. Barry Byrne, Md, MD | Pediatric Cardiology | Gainesville, FL | $11,812 | $0 |
| Andrew Siderowf, Md, MD | Neurology | Philadelphia, PA | $11,635 | $0 |
| Daniel Curry, Md, MD | Neurological Surgery | Houston, TX | $11,613 | $0 |
| Perry Shieh, Md, MD | Neuromuscular Medicine | Los Angeles, CA | $11,456 | $0 |
| Dr. Claudia Chiriboga, M.d, M.D | Neurology with Special Qualifications in Child Neurology | New York, NY | $11,452 | $0 |
| Dr. Stephen Cederbaum, M.d, M.D | Clinical Genetics (M.D.) | Los Angeles, CA | $11,304 | $0 |
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc. has made $56.6M in payments to 1,083 healthcare providers, recorded across 9,790 transactions in the CMS Open Payments database. In 2024, the company paid $8.4M. The top product by payment volume is EMFLAZA ($1.3M).
Payments were distributed across 89 medical specialties. The top specialty by payment amount is Contractor ($1.0M to 1 doctors).
Payment categories include: Food & Beverage ($98,485), Consulting ($2.8M), Research ($49.2M), Travel & Lodging ($294,283), Royalties ($482,303).
PTC Therapeutics, Inc. is associated with 2 products in the CMS Open Payments database.